Lycia Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 26.4 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.52B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune, inflammatory, and allergic diseases. The company develops the LYTAC platform, a modular technology designed to create therapeutics that selectively reduce the levels of pathogenic proteins. Its therapeutic candidate LCA-0061 degrades immunoglobulin E (IgE) for the treatment of allergic diseases, including food allergy. The company also develops LCA...